card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Blog

Q² Solutions Enhances Companion Diagnostics Capabilities in Collaboration with Illumina

Q² Solutions, a global clinical trials laboratory services organization, today announced the expansion of its genomic companion diagnostics (CDx) capabilities.
Home / Blog / Q² Solutions Enhances Companion Diagnostics Capabilities in Collaboration with Illumina

October 24, 2016

MORRISVILLE, N.C. – October 24, 2016 – Q2 Solutions, a global clinical trials laboratory services organization, today announced the expansion of its genomic companion diagnostics (CDx) capabilities. This comes as a result of an agreement between Q2 Solutions – EA Genomics and Illumina, a global leader in genomics, to establish a framework for developing next-generation sequencing-based (NGS) CDx assays. The expansion of Q2 Solutions’ CDx development portfolio will further enhance the company’s wide range of end-to-end services that extend from biomarker discovery and development to the application of precision medicine through its clinical trials laboratory network.

Under the terms of the agreement, Q2 Solutions will develop NGS assays using the Illumina MiSeqDx® instrument. The MiSeqDx is the first NGS instrument to be cleared by the U.S. Food and Drug Administration (FDA) for in vitro diagnostic purposes in clinical laboratories. This alliance brings together two industry-leading companies, combining Q2 Solutions’ global experience and local knowledge, as well as its deep genomic, scientific and medical expertise, with Illumina’s ability to apply innovative technologies to the analysis of genetic variation and function. 

“At Q2 Solutions, we partner with our customers to bring innovative solutions to meet the needs of patients across the world,” said Costa Panagos, chief executive officer, Q2 Solutions. “The industry is quickly moving toward a world of precision medicine, and we believe companion diagnostics are key to unlocking a new future for patients who are battling diseases, such as cancer, where more targeted and accurate therapies are critical. Q2 Solutions helped develop 62 percent of all FDA-approved precision medicine drugs of 2015, and we look forward to the opportunity to continue working with our customers on an approach that can help improve healthcare globally.”

To hear more about this opportunity, view this video (or watch below) featuring Kellie Yarnell, vice president of Genomics Laboratories, Q2 Solutions.


About Q2 Solutions
Launched in 2015, Q2 Solutions is a global clinical trials laboratory services organization that helps biopharmaceutical, medical device and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. Q2 Solutions is a joint venture formed by QuintilesIMS and Quest Diagnostics, combining the clinical trials laboratory services of each parent organization. To learn more, visit www.q2labsolutions.com.

 
 



Contacts:

Phil Bridges
QuintilesIMS Media Relations
phil.bridges@quintilesims.com
+919.998.1653 (office)
+1.919.457.6347 (mobile)

Todd Kasper
QuintilesIMS Investor Relations
todd.kasper@quintilesims.com
+1.919.998.2590 

Tor Constantino 
QuintilesIMS Media Relations
tor.constantino@quintilesims.com
+1.484.567.6732 (office / mobile)

Tom Kinsley
QuintilesIMS Investor Relations
tom.kinsley@quintilesims.com
+1.203.448.4691